The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant interest within the British Isles, prompting a notable shift in peptide trends. Availability these treatments remains a complex landscape, with public healthcare system provision currently limited and specialist practices offering treatment at a higher cost